Impax Laboratories Given Consensus Recommendation of "Hold" by Analysts
Shares of Impax Laboratories have been given a consensus recommendation of "Hold" by the sixteen analysts that are presently covering the company, Analyst Ratings Network.com reports .
Impax Labs get subpoena in price fixing probe
Besides price fixing, the investigation is also to determine if there was an allocation or dividing of customers or territories, the company said in a regulatory filing.
Rising heart drug price pulls Impax into Connecticut AG investigation
The foxglove plant is the source of digoxin, a drug used to control abnormal heart rhythms.
Impax Laboratories Price Target Raised to $35.00 at WallachBeth Capital
The firm currently has a "buy" rating on the stock. WallachBeth Capital's price objective would indicate a potential upside of 14.68% from the stock's previous close.
Impax Acquires Two Products from Actavis
Impax Laboratories, Inc. today announced that it has acquired from Actavis plc two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement.
Impax Laboratories to Announce Results for Second Quarter 2014 on August 6
Impax Laboratories, Inc. announced today that the Company will release its second quarter 2014 financial results on Wednesday, August 6, 2014, prior to the open of the U.S. financial markets.
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest
Actavis plc and Forest Laboratories, Inc. today announced that the U.S. Federal Trade Commission has voted to approve Actavis' proposed acquisition of Forest.
The Washington Post
Drugmaker Deals Blocking Generics Face New Probes by U.S.
U.S. regulators, armed with a year- old Supreme Court decision, are stepping up probes of pharmaceutical deals that delay the sale of generic drugs, arrangements they view as illegally hurting competition.